Loading…
Cullinan Therapeutics, Inc. is projected to rise to $21.96 by 2027, a +42% move from its current price of $15.52. CGEM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $14.95 | $15.52 | $16.11 | 0.00% |
| May 30 | $14.72 | $15.52 | $16.36 | +0.01% |
| May 31 | $14.55 | $15.52 | $16.56 | +0.01% |
| Jun 1 | $14.41 | $15.52 | $16.73 | +0.02% |
| Jun 2 | $14.28 | $15.52 | $16.87 | +0.02% |
| Jun 3 | $14.17 | $15.52 | $17.01 | +0.02% |
| Jun 4 | $14.06 | $15.52 | $17.14 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $14.06 | $15.52 | $17.14 | +0.03% |
| Week 2 | $13.50 | $15.53 | $17.86 | +0.06% |
| Week 3 | $13.09 | $15.53 | $18.43 | +0.08% |
| Week 4 | $12.75 | $15.54 | $18.93 | +0.11% |
| Week 5 | $12.46 | $15.54 | $19.38 | +0.14% |
| Week 6 | $12.20 | $15.55 | $19.80 | +0.17% |
| Week 7 | $11.97 | $15.55 | $20.20 | +0.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on therapies for autoimmune diseases and cancer in the United States. It develops multiple bispecific T cell engager programs, including CLN-978 (CD19xCD3) for autoimmune diseases in Phase 1, Velinotamig (BCMAxCD3) in Phase 1 for autoimmune diseases, and CLN-049 (FLT3xCD3) in Phase 1 for relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.
It is advancing Zipalertinib, an orally available EGFR inhibitor in Phase 2b for EGFR ex20ins NSCLC, and has a license with Chongqing Genrix Biopharmaceutical Co., Ltd, a co-development agreement with Taiho Pharmaceutical Co., Ltd, and a collaboration with Adimab, LLC. Cullinan Therapeutics was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc.
in April 2024. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
CGEM is the stock ticker for Cullinan Therapeutics, a Healthcare company with a current price of $15.46, a market cap of $950.14M, and a rank of 2579. The price outlook shows a path of upside in the coming years, with the average price forecast rising from $15.46 in 2026 to $30.69 in 2030, $94.07 in 2040, and $160.23 in 2050, reflecting a bullish long-term trajectory.
A major floor 30.9% below — a decisive break under it would weaken the trend.
The nearest floor, 17.5% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 18.6% above — clearing it would confirm fresh momentum.
Key CGEM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CGEM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $14.63 | Buy | $14.96 | Buy |
| MA 10 | $15.04 | Buy | $14.88 | Buy |
| MA 20 | $14.76 | Buy | $14.75 | Buy |
| MA 50 | $14.26 | Buy | $14.31 | Buy |
| MA 100 | $13.50 | Buy | $13.38 | Buy |
| MA 200 | $10.89 | Buy | $12.10 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 57.06 | Neutral |
| Stoch RSI (14) | 58.72 | Neutral |
| CCI (20) | 64.31 | Neutral |
| Williams %R (14) | -32.53 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | 6.67 | Buy |
| Bollinger %B (20,2) | 0.70 | Neutral |
| Stochastic %K (14) | 67.47 | Neutral |
| TRIX (15) | 0.22 | Buy |
| Awesome (5,34) | 0.12 | Buy |
| Ultimate (7,14,28) | 50.02 | Neutral |
| Momentum (10) | -0.63 | Sell |
| Aroon Osc (25) | 44.00 | Buy |
| Hull MA (9) | 14.69 | Buy |
| ADX (14) | 14.40 | Neutral |
| ATR (14) | 0.47 | Info |
The 30-day technical picture is bullish. RSI14 is 60, with a 50-day simple moving average of $14.23 and a 200-day simple moving average of $10.85. Near-term support is at $12.81 and resistance at $16.33, while the 30-day price range spans from $11.99 to $19.93.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.99 | $15.52 | $23.14 | 0% | Neutral | |
| $16.80 | $21.96 | $30.76 | +42% | Bullish | |
| $21.60 | $29.36 | $43.06 | +89% | Bullish | |
| $22.91 | $32.18 | $48.94 | +107% | Bullish | |
| $21.66 | $31.32 | $49.10 | +102% | Bullish | |
| $23.60 | $35.06 | $56.45 | +126% | Bullish | |
| $25.41 | $38.73 | $63.86 | +150% | Bullish | |
| $30.42 | $47.49 | $79.99 | +206% | Bullish | |
| $35.66 | $56.97 | $97.87 | +267% | Bullish | |
| $37.10 | $60.61 | $106.04 | +291% | Bullish | |
| $53.61 | $97.13 | $183.30 | +526% | Bullish | |
| $76.64 | $167.66 | $352.72 | +980% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $9.99 | $15.52 | $18.38 | +0.00% |
| June 2026 | $13.12 | $15.53 | $18.92 | +0.09% |
| July 2026 | $13.01 | $15.58 | $19.32 | +0.26% |
| August 2026 | $13.67 | $16.52 | $20.78 | +6.09% |
| September 2026 | $13.84 | $16.85 | $21.43 | +1.98% |
| October 2026 | $13.31 | $16.32 | $20.97 | -3.15% |
| November 2026 | $13.51 | $16.66 | $21.60 | +2.10% |
| December 2026 | $14.27 | $17.71 | $23.14 | +6.25% |
Click any year to see its month-by-month CGEM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cullinan Therapeutics, Inc.'s 2026 outlook centres on $15.52, within a $9.99 to $23.14 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CGEM could reach as high as $30.76, with a base case around $21.96 and support toward $16.80 — roughly +42% from $15.52. Momentum favours further upside here.
Expect CGEM to range from $21.60 to $43.06 through 2028. The $29.36 average target implies a +89% move from current prices. That is up +34% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CGEM price prediction for 2029 points to an average of $32.18 (low $22.91, high $48.94) — a potential gain of +107% on today's $15.52. Momentum favours further upside here.
In 2030, CGEM is projected to trade between $21.66 and $49.10, averaging $31.32 — a potential gain of +102% from today's $15.52. That is -3% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
Cullinan Therapeutics, Inc.'s 2031 outlook centres on $35.06, within a $23.60 to $56.45 range. That is up +12% on the projected 2030 average. That marks a +126% change versus current levels. Momentum favours further upside here.
By 2032, CGEM could reach as high as $63.86, with a base case around $38.73 and support toward $25.41 — roughly +150% from $15.52. Buyers look set to stay in control over this stretch.
Expect CGEM to range from $30.42 to $79.99 through 2033. The $47.49 average target implies a +206% move from current prices. That is up +23% on the projected 2032 average. Momentum favours further upside here.
The CGEM price prediction for 2034 points to an average of $56.97 (low $35.66, high $97.87) — a potential gain of +267% on today's $15.52. Buyers look set to stay in control over this stretch.
In 2035, CGEM is projected to trade between $37.10 and $106.04, averaging $60.61 — a potential gain of +291% from today's $15.52. That is up +6% on the projected 2034 average. Momentum favours further upside here.
Cullinan Therapeutics, Inc.'s 2040 outlook centres on $97.13, within a $53.61 to $183.30 range. That is up +60% on the projected 2035 average. That marks a +526% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CGEM could reach as high as $352.72, with a base case around $167.66 and support toward $76.64 — roughly +980% from $15.52. Momentum favours further upside here.
Investing $1,000 in CGEM today (≈ 64.43299 CGEM) could be worth
$10,802.88
+$9,802.88 (+980%) by 2050 · US Dollar
Based on the average projected CGEM price of $167.66 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CGEMwould be worth at today's price.
$1,000 invested in CGEM on May 27, 2025 (≈ 127.877235 CGEM) would be worth
$1,984.65
+$984.65 (+98.5%) today · 1.98× · US Dollar
Based on a CGEM entry price of $7.82 vs. today's $15.52.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.33 | $1,083.04 | +8.3% |
| 1 month ago | $13.25 | $1,171.32 | +17.1% |
| 3 months ago | $15.21 | $1,020.38 | +2.0% |
| 6 months ago | $11.37 | $1,365 | +36.5% |
| 1 year ago | $7.82 | $1,984.65 | +98.5% |
| All time (5.0y) ago | $29.1 | $533.33 | -46.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CGEM forecast.
Our base-case forecast reaches $31.00 around 2029.
Implied market cap at $31.00: $1.91B
The multi-year forecast shows a bullish trajectory with the average price rising across key future milestones: 2027 avg $21.73, 2028 avg $29.17, 2029 avg $31.83, 2030 avg $30.69 (ROI 98.5, sentiment BULLISH), 2031 avg $34.36, 2032 avg $37.74, 2033 avg $46.12, 2034 avg $55.65, 2035 avg $59.07 (all with bullish sentiment). The forecast continues to climb to 2040 avg $94.07 (ROI 508.5) and 2050 avg $160.23 (ROI 936.4), with sustained bullish sentiment through 2040 and 2050. These figures are estimates and not guarantees.
Tap a question to reveal the answer.
The forecasted average price is $30.69; the range is $21.05 to $48.51, with an ROI of 98.5 and sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with upside to 2035 and beyond; averages rise to $21.73 (2027), $30.69 (2030), $94.07 (2040), and $160.23 (2050), indicating meaningful upside relative to the current price of $15.46, though these are estimates, not guarantees.
Yes. The 2040 forecast includes a max of $179.65, which exceeds $100.
Current price is $15.46; Market cap $950.14M.
Bullish sentiment with RSI 60; SMA50 $14.23; SMA200 $10.85; support $12.81; resistance $16.33; 30-day range $11.99–$19.93.
Cullinan Therapeutics, Inc. Community Discussion
0Share your Cullinan Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.